Trial testing RejuvenAir device in chronic bronchitis is fully enrolled
COPD News Today
by Margarida Maia, PhD
2d ago
Enrollment is now complete in a clinical trial testing RejuvenAir, CSA Medical’s minimally invasive device, in adults with chronic bronchitis — one of the most common forms of chronic obstructive pulmonary disease (COPD). The trial, called SPRAY-CB (NCT03893370), enrolled 210 patients at sites across the U.S. and one in the U.K. nearly two months ahead of schedule. If positive, its data may support an application for approval of RejuvenAir in the U.S., where it has been designated a breakthrough device as an incentive to speed its development. The device already is cleared for use in Europe f ..read more
Visit website
How I eliminate the COPD ‘garden weeds’ of my mind
COPD News Today
by Caroline Gainer
5d ago
As a gardener, I sometimes imagine my mind as a garden full of various plants. Advocating for chronic obstructive pulmonary disease (COPD) patients while living with the disease myself sometimes causes a few weeds to grow in my mind. I’ve written about how advocacy helps me stay motivated. It also means, however, that I’m exposed to the negative thoughts and feelings of the people I’m trying to help. Whether the negative thought originated from me or someone else, it takes up residence in my brain, so I must be vigilant in replacing it with a positive one. I have lots of tools in my garden sh ..read more
Visit website
Dupixent now approved in EU to treat uncontrolled COPD
COPD News Today
by Lindsey Shapiro PhD
1w ago
Dupixent (dupilumab) has been approved by the European Commission as an add-on maintenance treatment for certain adults with uncontrolled chronic obstructive pulmonary disease (COPD). Specifically, the therapy from Sanofi and Regeneron Pharmaceuticals is now indicated for COPD patients in the European Union who have evidence of type 2 inflammation, characterized by an elevation of immune cells called eosinophils. Eligible patients also must have poorly controlled disease despite already being on maximal standard-of-care inhaled therapies, as appropriate. Such treatments include corticosteroid ..read more
Visit website
Let’s talk about COPD and incontinence
COPD News Today
by Caroline Gainer
2w ago
Incontinence ranks right up there with religion and politics as topics we don’t usually mention in polite company, partly because it’s embarrassing. But let’s discuss it anyway, because it affects many patients with chronic obstructive pulmonary disease (COPD). I’m fortunate to have never had an incident with incontinence in public. It was humiliating enough to be alone at my kitchen sink when the gush happened. My good fortune continues today as I have only occasional urinary incontinence. Back to that gush at my kitchen sink: I was coughing and gagging while rinsing the dishes, and a small ..read more
Visit website
Lung association launches resource hub for living with lung disease
COPD News Today
by Patricia Inácio, PhD
2w ago
The American Lung Association has launched the Wellness Hub, a resource designed to improve the everyday lives of people with chronic obstructive pulmonary disease (COPD) and other lung diseases. Wellness Hub content, including disease-specific online classes, live and on-demand webcasts, and educational resources for improving mental and physical health, is available for free to members of the association’s Patient & Caregiver Network. Membership is free and accessible to all. “Many lung diseases like COPD, pulmonary fibrosis (PF) and asthma have no cure, so a person will be living ..read more
Visit website
Ensifentrine, now Ohtuvayre, wins FDA approval for COPD
COPD News Today
by Marisa Wexler, MS
2w ago
The U.S. Food and Drug Administration (FDA) has approved Verona Pharma’s ensifentrine as an inhaled maintenance therapy for adults with chronic obstructive pulmonary disease (COPD). The decision makes ensifentrine — to be marketed under the brand name Ohtuvayre — the first therapy with a new mechanism of action to win approval for COPD in more than two decades. Importantly, the therapy is a nonsteroidal molecule with anti-inflammatory and airway-widening effects. It therefore is expected to effectively improve lung function, ease symptoms, and reduce the risk of exacerbations in COPD pat ..read more
Visit website
1 in 6 COPD US patients do not adhere to medication due to costs
COPD News Today
by Andrea Lobo
3w ago
One in six adults in the U.S. with chronic obstructive pulmonary disease (COPD) didn’t adhere to their medications due to costs, which is associated with a poor prognosis. That’s according to a study that analyzed data from a U.S. survey of adults with COPD between 2013-2020. Patients younger than 65, women, and those with a lower income or lacking health insurance were more likely to report cost-related medication nonadherence, results showed. “Targeted interventions based on the identified influencing factors in this study are recommended to enhance medication adherence among COPD patients ..read more
Visit website
A waiting game reminds me of being diagnosed with COPD
COPD News Today
by Caroline Gainer
1M ago
For two weeks, I’ve gone to at least two doctor appointments a week to learn what’s causing me stomach problems atop my chronic obstructive pulmonary disease (COPD), but I still don’t have a definitive answer. I’ve been having pain in the area of my hiatal hernia (in the diaphragm) as well as acid reflux, even though I’m taking 30 mg of Prevacid (lansoprazole) a day. COPD and acid reflux, also called gastroesophageal reflux disease (GERD), are considered comorbidities. As I was about to become agitated about the wait, I reminded myself that I went through something similar when I was diagnose ..read more
Visit website
Dupixent eases flares, aids lung function with COPD: NOTUS trial
COPD News Today
by Steve Bryson, PhD
1M ago
Dupixent (dupilumab) as an add-on maintenance treatment significantly eased exacerbations and lung symptom severity while improving lung function and quality of life — among people with moderate to severe chronic obstructive pulmonary disease (COPD). That’s according to published data from the Phase 3 NOTUS clinical trial (NCT04456673), which confirmed previous findings in the similarly designed Phase 3 BOREAS study (NCT03930732). “In my more than 20 years of practice, there have been limited advancements for patients struggling with the debilitating effects of uncontrolled COPD, and too many ..read more
Visit website
If I’d have hated smoking 6 decades ago, I might not have COPD today
COPD News Today
by Caroline Gainer
1M ago
If, 58 years ago, I had hated cigarettes as much as I hate them now, I probably wouldn’t have chronic obstructive pulmonary disease (COPD). However, that isn’t guaranteed, as two other risk factors likely increased my chances of developing the condition. The first is that I was born weighing just 4 pounds. Although I stayed in my mother’s belly for close to the proper amount of time, I was considered premature and was in an incubator for several days. According to Pursuit, the University of Melbourne’s media platform, researchers at the university found that preemies are at a 2.9 times higher ..read more
Visit website

Follow COPD News Today on FeedSpot

Continue with Google
Continue with Apple
OR